This trial aims to evaluate the effectiveness of raltitrexed/oxaliplatin/bevacizumab versus mFOLFOX6/bevacizumab in treating second-line metastatic colorectal cancer.
Phase II clinical trial design
Comparison between raltitrexed/oxaliplatin/bevacizumab and mFOLFOX6/bevacizumab
Evaluation of treatment outcomes in patients with metastatic colorectal cancer
Results demonstrate the efficacy of raltitrexed-based therapy in comparison to standard treatment
Detailed outcomes are provided in clinical trial registries